Navigation Links
MGH researchers describe new way to identify, evolve novel enzymes
Date:8/15/2007

The intricate interplay of proteins and other chemicals that underlies most biological activities requires the participation of enzymes, specialized molecules that accelerate chemical reactions between molecules. The creation of totally new enzymes can help improve the synthesis of chemicals and pharmaceuticals, devise new tools for molecular biology research, and develop new therapies. In the August 16 issue of Nature, two Massachusetts General Hospital (MGH) researchers describe a way of creating novel enzymes that, for the first time, does not require prior understanding of exactly how the enzymes work.

To date, the only source of enzymes has been biology, says Jack Szostak, PhD, of the MGH Department of Molecular Biology, the reports senior author. Great efforts are going into modifying and improving these natural enzymes, and our work demonstrates the potential of evolving completely new enzymes in the laboratory.

Szostak and his co-author Burckhard Seelig, PhD, used a technique called mRNA display previously developed in Szostaks lab that allows the identification and amplification of proteins that fit particular criteria. In order to create an enzyme that would stimulate or catalyze the joining of two segments of RNA in a way that does not occur naturally, they began by generating a library of 4 trillion small proteins with slight variations in their sequences. Each protein was then brought together with the RNA segments to be joined, called substrates.

If a particular protein induced the RNA substrates to join, resulting in a significantly larger molecule, that signified the protein was an active enzyme. The investigators could select out the larger RNA strands, generate more of the enzymes, and repeat the experiment. The induction of random mutations to produce different forms of the enzymes and reducing the time allowed for the splicing reaction enabled the development of more efficient versions by means of guided
'/>"/>

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
Source:Eurekalert

Page: 1 2

Related biology news :

1. Researchers discover way to make cells in the eye sensitive to light
2. Researchers find how protein allows insects to detect and respond to pheromones
3. Researchers Uncover Key Step In Manufacture of Memory Protein
4. NYU researchers simulate molecular biological clock
5. Researchers reveal the infectious impact of salmon farms on wild salmon
6. Researchers identify target for cancer drugs
7. Vital step in cellular migration described by UCSD medical researchers
8. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
9. UCSD researchers maintain stem cells without contaminated animal feeder layers
10. Researchers discover molecule that causes secondary stroke
11. Researchers find missing genes of ancient organism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2015)... , Feb. 23, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... provisional patent 62114357 for DISTRIBUTED VOICE DIRECTED ... NXT-ID introduces a new groundbreaking payment method. Payment accounts ... account may only be accessed if both the speech ...
(Date:2/13/2015)... 2015 ACT Genomics Co., Ltd., a ... transform cancer genomic information into precision diagnosis and ... raised US$ 8 million in the its first private ... Taipei, Taiwan , ACT Genomics has developed ... aim to implement next generation sequencing (NGS) and ...
(Date:2/11/2015)... February 11, 2015 ... "Access Control Market by Product (Cards and Readers, Biometrics, ... Defense, Government, Industrial, Healthcare, Education) and By Geography - Global ... MarketsandMarkets, the Access Control Market is expected ... at a CAGR of 10.6% between 2014 ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3ACT Genomics Raises $8 Million in its First Private Funding Round 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4
... travelling in Quartier Concordia along Ste. Catherine street or ... and see a demonstration of innovative Canadian technology conceived ... floors of one facade of an institutional building - ... This world-first demonstration of this type of combined solar ...
... attend the joint Congress of the International Osteoporosis Foundation ... of Osteoporosis and Osteoarthritis, to be held in Florence, ... is a unique opportunity for clinicians and researchers from ... 2010 in the field of osteoporosis and osteoarthritis. The,congress ...
... crying for more food at supper. Sadly, Margie Fischer doesn,t ... family,s dinner table for years. Her daughter Maggie, now 20, ... body can,t tolerate anything more than a low-protein diet. ... disease that is characterized by a deficiency in an enzyme ...
Cached Biology News:A world-first in solar technology unveiled at Concordia University 2New drug holds out promise of normal diet for sufferers of devastating PKU genetic disease 2New drug holds out promise of normal diet for sufferers of devastating PKU genetic disease 3
(Date:3/2/2015)... March 2, 2015  Pfenex Inc. (NYSE MKT: ... development of biosimilar therapeutics, today announced that it ... Healthcare Conference in Miami, FL at the Loews Miami Beach ... officer of Pfenex, will provide an overview of ... 12th at 9:00 am ET. A live audio webcast and ...
(Date:3/2/2015)... Kent, WA (PRWEB) March 02, 2015 ... tangential flow flat-sheet testing system at the 2015 AMTA ... is a culmination of a decade’s worth of engineering ... system compatible with a wide range of applications across ... be versatile enough to meet the dynamic needs of ...
(Date:2/27/2015)... February 27, 2015 Immunovaccine Inc. (“Immunovaccine” ... of a fraudulent press release disseminated this morning by ... from Immunovaccine. This press release states that Immunovaccine has ... The press release did not originate from Immunovaccine ... within the press release. Please note that all ...
(Date:2/27/2015)... February 27, 2015 Immunovaccine Inc. ... immunotherapy company, today announced that the U.S. Food ... Fast Track designation and Phase I clinical trials ... with the mutual co-development agreement signed with Gilead ... Track designation for the DPX-Survivac. , “We have ...
Breaking Biology Technology:Sterlitech Displays Complete CF042 Membrane Test System 2Immunovaccine Disclaims Hoax Press Release 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
... /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ) ... trials for three of the Company,s product candidates were ... Annual Meeting on May 30, 2009 in Orlando, Florida. ... 2b trial of Stimuvax(R) in patients with stage IIIB/IV ...
... best places to work in the biotechnology industry by The Scientist magazine. ... Wilmington, ... the best places to work in the biotechnology industry by The Scientist ... business were named in the top four by readers of The Scientist magazine ...
... Successfully Delivered into the Bloodstream- Data Demonstrates ... OxycodoneMELBOURNE, Australia, May 29 Phosphagenics Limited ... the successful completion of preclinical studies related ... The results of the preclinical studies demonstrated ...
Cached Biology Technology:Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting 3Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting 4Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting 5Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting 6DuPont Named Among Best Places to Work by The Scientist Magazine 2Phosphagenics Announces Completion of Transdermal Patch Prototypes 2Phosphagenics Announces Completion of Transdermal Patch Prototypes 3Phosphagenics Announces Completion of Transdermal Patch Prototypes 4
...
Rabbit polyclonal to Staphylococcus Enterotoxin A (HRP) ( Abpromise for all tested applications)....
... with a modular approach to instrument control, ... Plus NDS family provides modular software components ... management, giving you the flexibility to choose ... now and that can grow as your ...
... Best: DASGIPs Process Control integrates Process ... comprehensive documentation for cultivation processes. A ... pH, dissolved oxygen, temperature and agitation ... Profiles, e.g. constant or scheduled media ...
Biology Products: